Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amyloid-beta Clear all
Completed Phase 3 Interventional Results available

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

NCT01020838
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
21 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
8
States / cities
Sun City, Arizona • Stanford, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls

NCT00448799
View directory record Official record
Conditions
Alzheimers Disease
Interventions
[123-I] AV-83 Injection and Imaging Procedures
Radiation
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 12, 2008 · Synced Sep 22, 2026, 5:39 AM EDT
Terminated No phase listed Observational

Predicting Cognitive Decline From Androgen Deprivation Therapy

NCT05820932
View directory record Official record
Conditions
Prostate Cancer
Interventions
Blood-based assay, Cognitive assessments, Quality of Life Surveys
Genetic · Diagnostic Test · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 22, 2026, 5:39 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00870519
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
I-123-MNI-168, 123-I MNI-168
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 22, 2026, 5:39 AM EDT
Terminated Not applicable Interventional

Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid

NCT02343757
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
PET/MRI
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.

NCT00765115
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY450139, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 1, 2008 · Synced Sep 22, 2026, 5:39 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease

NCT00299988
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Intravenous Immunoglobulin, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 22, 2026, 5:39 AM EDT
Active, not recruiting Phase 1 Interventional

Study of AV-1959D, an Amyloid Beta Vaccine

NCT05642429
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AV-1959D, Placebo
Biological
Lead sponsor
Institute for Molecular Medicine
Other
Eligibility
60 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Newport Beach, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

NCT03522129
View directory record Official record
Conditions
Alzheimer Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain

NCT00287248
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] IMPY & SPECT Imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease

NCT00939822
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 72 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Fitchburg, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Phase 3 Interventional

Effect of LY2062430 on the Progression of Alzheimer's Disease

NCT00905372
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2062430, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
59
States / cities
Phoenix, Arizona • Sun City, Arizona • Tuscon, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Sep 22, 2026, 5:39 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition

NCT00657813
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MNI-330 as a brain SPECT tracer of Beta-Amyloid
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 22, 2026, 5:39 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

NCT07142278
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
Interventions
DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only)
Biological
Lead sponsor
Nuravax, Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 22, 2026, 5:39 AM EDT
Not listed Phase 3 Interventional

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

NCT01886820
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
[18F]NAV4694
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
15
States / cities
Sun City, Arizona • La Jolla, California • Fort Myers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

[C-11]PiB PET Imaging in Alcohol Use Disorders

NCT03746366
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
[C-11], Pittsburgh Compound B
Radiation · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 22, 2026, 5:39 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

NCT05731440
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction

NCT02063217
View directory record Official record
Conditions
Amyloid-beta
Interventions
Sodium Oxybate, Sleep deprivation
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Phase 2 Interventional

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

NCT00112073
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
bapineuzumab, placebo
Drug · Other
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
26
States / cities
Sun City, Arizona • Irvine, California • Los Alamitos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Phase 4 Interventional Results available

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

NCT00551161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
memantine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Phase 2 Interventional

Effect of Lithium and Divalproex in Alzheimer's Disease

NCT00088387
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Divalproex, Lithium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Phase 4 Interventional

N-of-1 for Beta-Blockers in Cardiac Amyloidosis

NCT05019027
View directory record Official record
Conditions
Cardiac Amyloidosis, Heart Diseases, TTR Cardiac Amyloidosis
Interventions
Beta blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 22, 2026, 5:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Plasma Abeta Responses to Stress

NCT05521919
View directory record Official record
Conditions
Stress Reaction, Stress Physiology
Interventions
Sympathetic Nervous System Activation, No-stress
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 22, 2026, 5:39 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

NCT05728736
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lemborexant 25 mg, Placebo
Drug
Lead sponsor
Brendan Lucey
Other
Eligibility
60 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 22, 2026, 5:39 AM EDT